<DOC>
	<DOCNO>NCT01492504</DOCNO>
	<brief_summary>The primary purpose study determine whether hepatitis C virus continue remain unable detected subject previously treat Asunaprevir ( BMS-650032 ) and/or Daclatasvir ( BMS-790052 ) achieve sustained virologic response .</brief_summary>
	<brief_title>Three-year Follow-up Study Subjects Who Participated Previous Asunaprevir ( BMS-650032 ) and/or Daclatasvir ( BMS-790052 ) Chronic Hepatitis C Clinical Trial</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<criteria>Inclusion Criteria Signed Written Informed Consent Subjects must receive least one dose Asunaprevir and/or Daclatasvir Subjects participate Daclatasvir and/or Asunaprevir study ( ie , protocol number begin AI443 , AI444 AI447 ) may enroll regardless virologic response Completed required posttreatment followup period previous study Must enroll study within 6 month complete previous BMS study within 6 month protocol availability clinical site Men woman , age 18 older Subject must treat antiviral immunomodulatory drug chronic hepatitis C ( CHC ) completion previous study Asunaprevir and/or Daclatasvir administer Subject must participate trial , exclude noninterventional trial Prisoners subject involuntarily incarcerate Subjects compulsorily detain treatment either psychiatric physical ( eg , infectious disease ) illness</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>